Synapse - Hematologic Malignancies, Division of

Results (13375)

Comparative analysis of clinical outcomes and healthcare resource utilization (HRU) in patients (pts) with newly diagnosed (nd) acute myeloid leukemia (aml) unfit for high-intensity chemotherapy treated with venetoclax (VEN) vs other therapies: Results from the AML real world evidence (ARC) initiative

Meeting Abstract

Desai, P.; Garcia, J. S.; Zeidner, J. F.; Abedin, S.; Wolach, O.; Vachhani, P.; Moshe, Y.; Pollyea, D. A.; Lai, C.; LeBlanc, T. W.; more...
Blood (2023)

Fulltext@MSK | Save

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma treated with venetoclax: A multicenter retrospective analysis

Meeting Abstract

Sawalha, Y.; Sarosiek, S. R.; Welkie, R. L.; Seif, S.; Thapa, S.; Zanwar, S.; Cahill, K.; Treitman, R.; Shah, H.; Arora, S.; more...
Blood (2023)

Fulltext@MSK | Save

Lisocabtagene maraleucel (liso-cel) in patients (pts) with R/R MCL: Subgroup analyses in pts with high-risk disease features from the MCL cohort of the TRANSCEND NHL 001

Meeting Abstract

Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M. A.; Hirayama, A. V.; Abramson, J. S.; Arnason, J. E.; Ghosh, N.; Mehta, A.; more...
Blood (2023)

Fulltext@MSK | Save

Revumenib monotherapy in patients with relapsed/refractory KMT2Ar acute leukemias: Efficacy and safety results from the AUGMENT-101 phase 1/2 study

Meeting Abstract

Aldoss, I.; Issa, G. C.; Thirman, M. J.; DiPersio, J.; Arellano, M.; Blachly, J. S.; Mannis, G.; Perl, A.; Dickens, D.; McMahon, C. M.; more...
Blood (2023)

Fulltext@MSK | Save

Impact of type of hypomethylating agent (HMA) used on outcomes of patients (pts) with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) - A large, multicenter, retrospective analysis

Meeting Abstract

Bewersdorf, J. P.; Kewan, T.; Blaha, O.; Stahl, M.; Al Ali, N. H.; DeZern, A. E.; Sekeres, M. A.; Uy, G. L.; Carraway, H. E.; Desai, P.; more...
Blood (2023)

Fulltext@MSK | Save

Dexamethasone is associated with a lower incidence and severity of cytokine release syndrome compared with other corticosteroid regimens when given as premedication for glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL)

Meeting Abstract

Falchi, L.; Carlo-Stella, C.; Morschhauser, F.; Dickinson, M.; Bachy, E.; Cartron, G.; Khan, C.; Tani, M.; Martinez-Lopez, J.; Bartlett, N. L.; more...
Blood (2023)

Fulltext@MSK | Save

Long-term results from the OPTIC trial: A dose-optimization study of 3 starting doses of ponatinib

Meeting Abstract

Cortes, J.; Deininger, M.; Lomaia, E.; Moiraghi, B.; Undurraga, S.; Pavlovsky, C.; Chuah, C.; Sacha, T.; Lipton, J. H.; McCloskey, J.; more...
Blood (2023)

Fulltext@MSK | Save

Influence of pre-treatment features and therapy choice by physicians on overall survival in older adults with acute myeloid leukemia: A report from the beat AML master trial

Meeting Abstract

Borate, U. M.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Madanat, Y. F.; Patel, P. A.; Collins, R. H.; more...
Blood (2023)

Fulltext@MSK | Save

A phase 1 study of PIT565, a first-in-class, anti-CD3, anti-CD19, anti-CD2 trispecific antibody in patients with relapsed and/or refractory B-cell malignancies

Meeting Abstract

Mazza, I. A.; Barba, P.; Yuda, J.; Palomba, M. L.; Alderuccio, J. P.; De Vriendt, C.; Corradini, P.; Lim, F. L. W. I.; Zinzani, P. L.; Jain, N.; more...
Blood (2023)

Fulltext@MSK | Save

Updated safety and efficacy results of ABBV-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed/refractory multiple myeloma

Meeting Abstract

Vij, R.; Kumar, S. K.; D'Souza, A.; McKay, J. T.; Voorhees, P. M.; Chung, A.; Tuchman, S. A.; Korde, N.; Weisel, K.; Teipel, R.; more...
Blood (2023)

Fulltext@MSK | Save